<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>House of Commons Science and Technology Committee Inquiry into Blood, Tissue and Organ Screening and vCJD</title></head><body><div><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">Written evidence submitted by </span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">the British Transplantation </span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">S</span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">ociety</span><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold"> (BTO0016)</span></p><p style="margin:0pt"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt; font-variant:small-caps">The British Transplantation Society</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">The British Transplantation Society (the BTS) is the professional voice of transplantation in the UK, representing all the varied disciplines in transplantation including clinicians, nurses, pharmacists, scientists involved both in basic research and in histocompatibility laboratories, ethicists and other professions allied to medicine.</span><span style="font-family:'Times New Roman'; font-size:12pt">  </span><span style="font-family:'Times New Roman'; font-size:12pt">The BTS was formed in 1972 and its membership is open to all professionals working i</span><span style="font-family:'Times New Roman'; font-size:12pt">n the field of transplantation.  The BTS works closely with key agencies involved in the delivery of the transplant service, in particular, NHS Blood and Transplant.  BTS members have contributed significantly to the </span><span style="font-family:'Times New Roman'; font-size:12pt">The Advisory Committee on the Safety of Blood, Tissues and Organs (</span><span style="font-family:'Times New Roman'; font-size:12pt">SaBTO</span><span style="font-family:'Times New Roman'; font-size:12pt">)</span><span style="font-family:'Times New Roman'; font-size:12pt"> which issued guidelines on minimisation of risk of transmission of vCJD through solid organ transplantation in March 2012.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt; font-variant:small-caps">Clinical and financial benefits of transplantation</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">Transplantation is the treatment of choice for end-stage failure of a number of organs.  The procedure is life-saving for recipients of cardiothoracic, liver and intestinal transplants and improves quality of life for most renal transplant recipients and improves life-expectancy for many.  Transplantation of whole pancreata or pancreatic islets has a major impact on the lives of diabetics.  Renal transplantation is a highly cost-effective treatment for end-stage renal failure with costs less than half of those for dialysis</span><a name="_GoBack"></a><span style="font-family:'Times New Roman'; font-size:12pt">.  Access to transplantation is limited by the availability of donor organs.  Insufficient availability results in 20% of patients on the waiting list for liver or cardiothoracic organs dying or becoming too ill to transplant and kidney transplant recipients waiting for an average of just over three years. </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt; font-variant:small-caps">Risk of disease transmission by solid organ transplantation</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">The potential for inadvertent transmission of cancer or infection in a transplanted organ is a key driver to the approach to assessing the suitability of a potential deceased organ donor.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">Currently, there is no specific screening test available for vCJD.  </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">Individuals with </span><span style="font-family:'Times New Roman'; font-size:12pt">probable or possible </span><span style="font-family:'Times New Roman'; font-size:12pt">CJD and vCJD and</span><span style="font-family:'Times New Roman'; font-size:12pt"> individuals whose blood relatives have had familial CJD, </span><span style="font-family:'Times New Roman'; font-size:12pt">or </span><span style="font-family:'Times New Roman'; font-size:12pt">other neurodegenerative diseases associated with infectious agents</span><span style="font-family:'Times New Roman'; font-size:12pt"> are excluded from organ donation in the UK</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">(</span><a href="http://odt.nhs.uk/pdf/contraindications_to_organ_donation.pdf"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:12pt; text-decoration:underline">http://odt.nhs.uk/pdf/contraindications_to_organ_donation.pdf</span></a><span style="font-family:'Times New Roman'; font-size:12pt">). </span><span style="font-family:'Times New Roman'; font-size:12pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt; font-variant:small-caps">Potential risk of transmission of vCJD and likely clinical impact</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">The incidence of vCJD in the UK over the last five years has amounted to only 1-2 diagnoses/deaths per year (data from UK Creutzfeldt Jakob Disease Surveillance Unit, </span><a href="http://www.cjd.ed.ac.uk"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:12pt; text-decoration:underline">www.</span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:12pt; font-weight:bold; text-decoration:underline">cjd</span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:12pt; text-decoration:underline">.ed.ac.</span><span style="color:#0000ff; font-family:'Times New Roman'; font-size:12pt; font-weight:bold; text-decoration:underline">uk</span></a><span style="font-family:'Times New Roman'; font-size:12pt; font-weight:bold">).  </span><span style="font-family:'Times New Roman'; font-size:12pt">While it is theoretically possible, t</span><span style="font-family:'Times New Roman'; font-size:12pt">here </span><span style="font-family:'Times New Roman'; font-size:12pt">have</span><span style="font-family:'Times New Roman'; font-size:12pt"> been no </span><span style="font-family:'Times New Roman'; font-size:12pt">documented cases of</span><span style="font-family:'Times New Roman'; font-size:12pt"> transmission of vCJD throug</span><span style="font-family:'Times New Roman'; font-size:12pt">h an organ or tissue transplant.  The theoretical unlikely risk of transmission of vCJD to solid organ transplant recipients must be balanced against the risks of restricting access to life saving transplants for individuals with end-stage organ failure.  These patients usually have multiple comorbidities and  </span><span style="font-family:'Times New Roman'; font-size:12pt">most recipients of organs retrieved from donors who might be harbouring vCJD will die from competing causes long before vCJD becomes clinically manifest. </span><span style="font-family:'Times New Roman'; font-size:12pt"> </span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt; font-variant:small-caps">Conclusion</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">We believe that current measures adopted by the UK transplant system are sufficient to render an acceptably low risk of inadvertent transmission of vCJD.  We would oppose more </span><span style="font-family:'Times New Roman'; font-size:12pt">restrictive measures that would reduce the number of suitable donor organs available for transplantation.</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt; font-style:italic">January 2014</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:12pt">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p></div></body></html>